Regeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
11 Dezembro 2023 - 9:30AM
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its
inclusion on the Dow Jones Sustainability World Index (DJSI World)
for the fifth consecutive year, alongside its fourth consecutive
inclusion on the Dow Jones Sustainability North America Index (DJSI
North America). These consistent rankings reflect the company's
continued dedication to sustainability and highlight Regeneron’s
belief that advancing environmental, social and governance (ESG)
practices is fundamental to the long-term resiliency and ethical
foundation of both our business and society as a whole.
The DJSI World Index represents the gold standard in corporate
responsibility rankings, acknowledging the top 10 percent of the
world's most sustainable companies in each industry. This year,
Regeneron stands proud as one of only five biotechnology firms
globally to make the list, ranking among the top 2 percent.
Regeneron’s sustained top ranking reflects its deep-rooted
commitment to corporate responsibility and highlights its
pioneering spirit in the biotechnology sector. The main areas of
the company’s improvement in this year’s assessment were climate
strategy, labor practice indicators, and tax strategy.
“Over the past 35 years, we’ve pushed the boundaries of
scientific discovery while relentlessly driving towards a healthier
and more sustainable future for our communities globally,” said
Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President, and
Chief Executive Officer of Regeneron. “Our consistent inclusion in
the DJSI World Index is an important testament to this commitment,
carried out daily by our extraordinary team of over 13,000
employees worldwide. As we continue our pursuit of the discovery
and development of life-changing medicines – promoting access to
our medicines, upholding high ethical standards and protecting the
environment remain central to our strategy of achieving responsible
growth.”
Regeneron’s journey towards its 2025 global responsibility goals
is guided by leading frameworks. The company is focused on three
key areas: improving the lives of patients with serious diseases,
fostering a culture of integrity and excellence and building
sustainable communities. Regeneron’s annual Responsibility Report
offers a transparent and comprehensive view of its initiatives and
progress.
“Regeneron’s 2025 responsibility goals encapsulate our ambition
to leverage our unique skills and resources for the greater good,”
said Christina Chan, Senior Vice President, Corporate Affairs at
Regeneron. “As we work towards these milestones, we aim to set new
benchmarks for what it means to be a leader at the intersection of
science and society. It's an exciting time at Regeneron, and we
look forward to continuing this journey, creating a more
sustainable future for all along the way.”
Regeneron's commitment to corporate responsibility is reflected
in its impressive performance across various top ESG ratings and
rankings. Beyond its inclusion in both the DJSI World and North
America indices, the company has ranked in the top 2 percent in the
Sustainalytics Risk Rating, and the top 10% in the ISS ESG
Corporate Rating.1 These recognitions underscore Regeneron's
impactful contributions to society and the environment.
Rating |
Industry Ranking1 |
S&P Global Corporate Sustainability Assessment |
Top 2% |
Sustainalytics Risk Rating |
Top 2% |
MSCI ESG Rating |
Top 16% - 39% |
ISS ESG Corporate Rating |
Top 10% |
FTSE4Good |
Top 13% |
1 As of Dec 11, 2023
About Regeneron Regeneron (NASDAQ: REGN)
is a leading biotechnology company that invents life-transforming
medicines for people with serious diseases. Founded and led for 35
years by physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to numerous
FDA-approved treatments and product candidates in development,
almost all of which were homegrown in our laboratories. Regeneron’s
medicines and pipeline are designed to help patients with eye
diseases, allergic and inflammatory diseases, cancer,
cardiovascular and metabolic diseases, hematologic conditions,
infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary VelociSuite®
technologies, such as VelocImmune®, which uses unique genetically
humanized mice to produce optimized fully human antibodies and
bispecific antibodies, and through ambitious research initiatives
such as the Regeneron Genetics Center, which is conducting one of
the largest genetics sequencing efforts in the world.
For additional information about Regeneron, please
visit www.regeneron.com or follow Regeneron
on LinkedIn.
Media Contacts: Joseph Brown,
Regeneron386-283-1323Joseph.Brown2@regeneron.com
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Regeneron Pharmaceuticals (NASDAQ:REGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024